FluocinonideCAS# 356-12-7 |
- Etifoxine
Catalog No.:BCC1560
CAS No.:21715-46-8
- Etomidate
Catalog No.:BCC1150
CAS No.:33125-97-2
- Etifoxine hydrochloride
Catalog No.:BCC1561
CAS No.:56776-32-0
- Acamprosate calcium
Catalog No.:BCC1327
CAS No.:77337-73-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 356-12-7 | SDF | Download SDF |
| PubChem ID | 9642 | Appearance | Powder |
| Formula | C26H32F2O7 | M.Wt | 494.52 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 100 mg/mL (202.22 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| SMILES | CC(=O)OCC(=O)C12C(CC3C1(CC(C4(C3CC(C5=CC(=O)C=CC54C)F)F)O)C)OC(O2)(C)C | ||
| Standard InChIKey | WJOHZNCJWYWUJD-IUGZLZTKSA-N | ||
| Standard InChI | InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Fluocinonide (Vanos) is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders.
Target: Glucocorticoid Receptor
Fluocinonide is a potent glucocorticoid steroid used topically as an anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis. Fluocinonide ranks as a high-potency topical corticosteroid. Minimal amounts should be used for a minimal length of time to avoid the occurrence of adverse effects. Fluocinonide should not be used if infection is present. Fluocinonide is used in veterinary medicine. It is a treatment for allergies in dogs. Natural systemic cortisol concentrations can be suppressed for weeks after one week of topical exposure. From Wikipedia. References: | |||||
Fluocinonide Dilution Calculator
Fluocinonide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0222 mL | 10.1108 mL | 20.2216 mL | 40.4433 mL | 50.5541 mL |
| 5 mM | 0.4044 mL | 2.0222 mL | 4.0443 mL | 8.0887 mL | 10.1108 mL |
| 10 mM | 0.2022 mL | 1.0111 mL | 2.0222 mL | 4.0443 mL | 5.0554 mL |
| 50 mM | 0.0404 mL | 0.2022 mL | 0.4044 mL | 0.8089 mL | 1.0111 mL |
| 100 mM | 0.0202 mL | 0.1011 mL | 0.2022 mL | 0.4044 mL | 0.5055 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Fluocinonide
- Betmidin
Catalog No.:BCN8253
CAS No.:35589-22-1
- tert-Butyl rosuvastatin
Catalog No.:BCC9163
CAS No.:355806-00-7
- N,N-dimethyl-2-Quinoxalinamine
Catalog No.:BCC9066
CAS No.:35552-76-2
- Buflomedil HCl
Catalog No.:BCC4760
CAS No.:35543-24-9
- YM-155 hydrochloride
Catalog No.:BCC2066
CAS No.:355406-09-6
- 6'-O-p-Hydroxybenzoylcatalposide
Catalog No.:BCN5297
CAS No.:355143-38-3
- Ki16425
Catalog No.:BCC1155
CAS No.:355025-24-0
- Ki16198
Catalog No.:BCC4560
CAS No.:355025-13-7
- TCS 1205
Catalog No.:BCC7819
CAS No.:355022-97-8
- 3-beta-O-(trans-p-Coumaroyl)maslinic acid
Catalog No.:BCN1452
CAS No.:35482-91-8
- Balicatib
Catalog No.:BCC5139
CAS No.:354813-19-7
- SC-514
Catalog No.:BCC4554
CAS No.:354812-17-2
- Darapladib
Catalog No.:BCC1515
CAS No.:356057-34-6
- Toceranib
Catalog No.:BCC2005
CAS No.:356068-94-5
- N-Desethyl Sunitinib
Catalog No.:BCC1792
CAS No.:356068-97-8
- CP 20961
Catalog No.:BCC6063
CAS No.:35607-20-6
- Mesuaxanthone A
Catalog No.:BCN5298
CAS No.:3561-81-7
- Benzbromarone
Catalog No.:BCC4634
CAS No.:3562-84-3
- NSC 3852
Catalog No.:BCC2423
CAS No.:3565-26-2
- SB-505124 hydrochloride
Catalog No.:BCC1930
CAS No.:356559-13-2
- SB525334
Catalog No.:BCC2531
CAS No.:356559-20-1
- Fmoc-Ala-OH
Catalog No.:BCC3034
CAS No.:35661-39-3
- Fmoc-Phe-OH
Catalog No.:BCC3535
CAS No.:35661-40-6
- Fmoc-Leu-OH
Catalog No.:BCC3509
CAS No.:35661-60-0
Adherence to a five day treatment course of topical fluocinonide 0.1% cream in atopic dermatitis.[Pubmed:24139369]
Dermatol Online J. 2013 Oct 16;19(10):20029.
BACKGROUND: Adherence in the treatment of chronic inflammatory skin diseases such as atopic dermatitis is poor. Methods to improve adherence have proven difficult. PURPOSE: To determine whether a short course of treatment with a high-potency corticosteroid will improve adherence compared to longer treatment studies and if improvement in disease and itch continues after treatment. METHODS: 10 patients with mild to moderate atopic dermatitis were instructed to apply Fluocinonide 0.1% cream twice daily for 5 days. Adherence was self-reported and electronically monitored. Treatment outcomes were assessed in terms of Visual Analog Scale of Itch (VAS), Eczema Area and Severity Index (EASI), and Investigator Global Assessment (IGA) scores. RESULTS: The median adherence rate was 40% (range of 0-100). The median percent change in VAS from baseline measures on days 7 and 14 were 90% (range -13, 100, p=0.02) and 52% (range 0, 100, p=0.004). On days 7 and 14, 20% and 70% patients achieved an EASI-75 and 40% and 60% an IGA of 0 or 1. LIMITATIONS: Small sample size limited subgroup analyses. CONCLUSIONS: Adherence rates with short-term treatment were similar to previously reported rates in longer term treatment studies. However, even non-adherent patients had significant improvement in itch and disease severity.
Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis.[Pubmed:20729956]
J Clin Aesthet Dermatol. 2009 Sep;2(9):24-32.
OBJECTIVE: To assess the efficacy and safety of topical Fluocinonide 0.1% cream for the treatment of atopic dermatitis. DESIGN: In this double-blind, vehicle-controlled study, patients were randomized to receive treatment with Fluocinonide 0.1% cream applied once (n=109) or twice daily (n=102) or vehicle applied once (n=50) or twice daily (n=52) for two weeks. SETTING: Multicenter, outpatient. PARTICIPANTS: Patients aged 18 years or older with atopic dermatitis affecting at least two percent but less than 10 percent of body surface area. MEASUREMENTS: Efficacy and safety measures included lesion severity, pruritus, hypothalamic-pituitary-adrenal axis suppression, and adverse events. RESULTS: Fluocinonide 0.1% cream applied once or twice daily was more effective than cream vehicle. Both regimens were similarly efficacious after two weeks of treatment. At the end of treatment, lesions were cleared or almost cleared in 59 percent of subjects treated once daily and 57 percent of subjects treated twice daily with Fluocinonide 0.1% cream. Further, considerable residual benefit remained after cessation of twice-daily versus once-daily treatment. Skin safety evaluations showed no significant adverse effects of treatment on signs or symptoms of skin atrophy. Fluocinonide 0.1% cream and vehicle treatments did not differ significantly in their suppression of the hypothalamic-pituitary-adrenal axis, nor did hypothalamic-pituitary-adrenal axis suppression differ significantly following once- or twice-daily treatment with Fluocinonide 0.1% cream. Fluocinonide 0.1% cream was well tolerated. CONCLUSION: Once- or twice-daily topical application of Fluocinonide 0.1% cream for 14 days was safe and effective for treating atopic dermatitis in this adult patient population. The efficacy of once-daily application was comparable to twice-daily application.
Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis.[Pubmed:21283922]
J Drugs Dermatol. 2011 Feb;10(2):171-6.
OBJECTIVE: To determine the effect a novel formulation of Fluocinonide cream on skin barrier function in subjects with atopic dermatitis. DESIGN: The authors performed an open-label, investigator-blinded, side-by-side, controlled trial examining skin barrier function before and after a two-week course of a class I, super-potent topical steroid. SETTING: Outpatient university-based dermatology clinic in Portland, OR. SUBJECTS: Twenty-five subjects aged 12 or older with a diagnosis of moderate, severe, or very severe AD were recruited for this study. INTERVENTION: Fluocinonide 0.1% cream, a novel formulation of a class I super-potent topical steroid was applied to all affected areas, except a control site, once daily for two weeks or until clear. The control target site was treated with the vehicle once daily. MAIN OUTCOME MEASURE(S): The study's primary outcome was change in skin barrier function as measured by basal transepidermal water loss (TEWL) in acute lesional skin from baseline as measured at two weeks. RESULTS: TEWL readings significantly decreased (reflecting improved barrier function) in both the active and control target sites. The active target site decreased 14.35+/-16 mg/cm2 per hour; 95 percent confidence interval, P<0.001. The control target site decreased 8.75+/-11.80 mg/cm2 per hour in 25 subjects; 95 percent confidence interval, P<0.001. Skin electrical capacitance also improved significantly, reflecting improved stratum corneum hydration with therapy. Pruritus, clinical severity, and quality of life scores all showed significant improvement by the end of the study. CONCLUSION: The authors have shown that short-term treatment with a novel formulation of 0.1% Fluocinonide led to significantly improved barrier function as measured by basal TEWL in subjects with active moderate to severe AD. These data suggest short-term treatment with AD with a super-potent corticosteroid improves skin barrier function.
Improvement in treatment adherence with a 3-day course of fluocinonide cream 0.1% for atopic dermatitis.[Pubmed:21140931]
Cutis. 2010 Oct;86(4):208-13.
Variations in adherence may cause variations in treatment outcomes with topical corticosteroid therapy for atopic dermatitis. An intensive short course of outpatient treatment may promote good adherence and provide a high level of efficacy. The purpose of this study was to assess the efficacy, tolerability, and adherence to short-term treatment with Fluocinonide cream 0.1% in the treatment of atopic dermatitis. Twenty participants with mild to severe atopic dermatitis were instructed to use Fluocinonide cream 0.1% twice daily for 3 consecutive days for a total of 6 doses. Disease severity was assessed at baseline, day 3, day 7, and day 14. Electronic monitoring was used to measure adherence to treatment. Median adherence to treatment over the 3-day period was 100%. By day 14, the median visual analog scale (VAS) of pruritus and eczema area and severity index (EASI) scores improved from baseline by 79% and 76%, respectively. By the end of the study period, 11 participants had investigator global assessment (IGA) scores of clear or almost clear. The absolute degree of improvement was proportional to baseline disease severity. Short-term treatment with Fluocinonide cream 0.1% for atopic dermatitis was well-tolerated and resulted in significant disease improvement (P < .001). Participants were highly adherent to the 3-day treatment regimen. Efforts to improve adherence may be valuable approaches for treating recalcitrant atopic dermatitis.
